Xihua Pharma

Xihua Pharma, founded in 2021, operates as a specialized subsidiary of Shanghai Xihua Scientific, focusing on comprehensive drug development and manufacturing services. The company provides an integrated CMC platform designed to support the entire pharmaceutical lifecycle, ranging from preclinical research to commercial-scale manufacturing. Their technical capabilities encompass API process R&D, advanced formulation development, and regulatory affairs, catering to both small and large molecule projects. Furthermore, Xihua Pharma maintains specialized expertise in gene and cell therapy products, positioning itself as a critical partner for innovative biotech firms seeking end-to-end development solutions.

The organization currently maintains a workforce of 500-1,000 employees, facilitating high-level operational efficiency across its primary facility in Shanghai, China. By leveraging a one-stop service model, the company streamlines complex R&D workflows, ensuring that pharmaceutical clients can accelerate their time-to-market while adhering to stringent regulatory standards. Meet Xihua Pharma's team to understand the leadership and technical expertise driving these integrated service offerings. Their commitment to customized solutions allows for precise alignment with client-specific drug development requirements, fostering long-term partnerships within the global healthcare sector.

Operating within the competitive pharmaceutical landscape, Xihua Pharma utilizes its robust infrastructure to address the evolving needs of the industry. The company’s focus on high-quality manufacturing and scientific rigor ensures that they remain a pivotal player in the development of next-generation therapeutics. Through continuous investment in their CMC platform, they empower pharmaceutical R&D initiatives, ultimately aiming to improve patient outcomes through reliable, scalable, and innovative manufacturing processes.